You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
European Medicines Agency committee recommends Pfizer's arthritis drug
State Of Singapore Online Video Subscription
Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition
Episode 43 - More Change, M&A On Horizon For Equity Research Industry
Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets
The European Medicines Agency's Committee for Medicinal Products for Human Use made a recommendation in favor of Pfizer Inc.'s Lifmior to treat rheumatoid arthritis and other forms of arthritis, as well as plaque psoriasis.
The drug is identical to Amgen's Enbrel, which was authorized in the EU in 2000. Lifmior is still subject to approval by the European Commission.